Uso de deucravacitinib oral para el manejo de placa psoriásica moderada a severa: ¿es efectivo?
Contenido principal del artículo
Keywords
Citas
1. Badri T, Kumar P, Oakley AM. Plaque Psoriasis. [Updated 2022 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430879/
2. Coates LC, Corp N, van der Windt DA, O'Sullivan D, Soriano ER, Kavanaugh A. GRAPPA Treatment Recommendations: 2021 Update. J Rheumatol. 2022; 49(6-S1):52-54.
3. Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023; 88(1):40-51.
4. Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, et al. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatol Ther (Heidelb). 2022; 12(2):495-510.
5. Gooderham MJ, Hong HC, Litvinov IV. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis. Skin Therapy Lett. 2022; 27(6):1-5.
6. Lé AM, Puig L, Torres T. Deucravacitinib for the Treatment of Psoriatic Disease. Am J Clin Dermatol. 2022; 23(6):813-822.
7. Picón-Jaimes YA, López-Medina IL, Carmona-Gómez JK, Filorio-Campos YP. Epidermólisis bullosa distrófica recesiva: avances e impacto del desarrollo de terapias génicas y alogénicas. Health Care & Global Health. 2022; 6(2):93-4.
8. Picón Jaimes YA, Orozco Chinome JE, Lozada ID, Moscote Salazar LR. Enfermedad, eutanasia y aborto: una reflexión desde la bioética. Revista Médica Risaralda. 2021; 27(1):4-9.
9. Picón-Jaimes YA, Lozada-Martinez ID, Orozco-Chinome JE, Montaña-Gómez LM, Bolaño-Romero MP, Moscote-Salazar LR, et al. Euthanasia and assisted suicide: An in-depth review of relevant historical aspects. Ann Med Surg (Lond). 2022; 75:103380.
2. Coates LC, Corp N, van der Windt DA, O'Sullivan D, Soriano ER, Kavanaugh A. GRAPPA Treatment Recommendations: 2021 Update. J Rheumatol. 2022; 49(6-S1):52-54.
3. Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023; 88(1):40-51.
4. Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, et al. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatol Ther (Heidelb). 2022; 12(2):495-510.
5. Gooderham MJ, Hong HC, Litvinov IV. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis. Skin Therapy Lett. 2022; 27(6):1-5.
6. Lé AM, Puig L, Torres T. Deucravacitinib for the Treatment of Psoriatic Disease. Am J Clin Dermatol. 2022; 23(6):813-822.
7. Picón-Jaimes YA, López-Medina IL, Carmona-Gómez JK, Filorio-Campos YP. Epidermólisis bullosa distrófica recesiva: avances e impacto del desarrollo de terapias génicas y alogénicas. Health Care & Global Health. 2022; 6(2):93-4.
8. Picón Jaimes YA, Orozco Chinome JE, Lozada ID, Moscote Salazar LR. Enfermedad, eutanasia y aborto: una reflexión desde la bioética. Revista Médica Risaralda. 2021; 27(1):4-9.
9. Picón-Jaimes YA, Lozada-Martinez ID, Orozco-Chinome JE, Montaña-Gómez LM, Bolaño-Romero MP, Moscote-Salazar LR, et al. Euthanasia and assisted suicide: An in-depth review of relevant historical aspects. Ann Med Surg (Lond). 2022; 75:103380.